EUROPEAN JOURNAL OF
PHARMACEUTICAL AND MEDICAL RESEARCH

An International Peer Reviewed Journal for Pharmaceutical, Medical & Biological Sciences

An Official Publication of Society for Advance Healthcare Research (Reg. No. : 01/01/01/31674/16)

European Journal of Pharmaceutical and Medical Research (EJPMR) has indexed with various reputed international bodies like : Google Scholar , Indian Science Publications , InfoBase Index (In Process) , SOCOLAR, China , Research Bible, Fuchu, Tokyo. JAPAN , International Society for Research activity (ISRA) , Scientific Indexing Services (SIS) , Polish Scholarly Bibliography , Global Impact Factor (GIF) (Under Process) , Universal Impact Factor , International Scientific Indexing (ISI), UAE  , Index Copernicus , CAS (A Division of American Chemical Society) USA (Under Process) , Directory of Open Access Journal (DOAJ, Sweden, in process) , UDLedge Science Citation Index , CiteFactor , Directory Of Research Journal Indexing (DRJI) , Indian citation Index (ICI) , Journal Index (JI, Under Process) , Directory of abstract indexing for Journals (DAIJ) , Open Access Journals (Under Process) , Impact Factor Services For International Journals (IFSIJ) , Cosmos Impact Factor , Jour Informatics (Under Process) , Eurasian Scientific Journal Index (ESJI) , International Innovative Journal Impact Factor (IIJIF) , Science Library Index, Dubai, United Arab Emirates , Pubmed Database [NLM ID: 101669306] (Under Process) , 

 ISSN 2394- 3211

Impact Factor: 4.161

 ICV - 79.57

Abstract

COMPARATIVE STUDY BETWEEN ORAL NIFEDIPINE AND INTRAVENOUS LABETALOL IN MANAGEMENT OF SEVERE PREGNANCY INDUCED HYPERTENSION

Prof. S. Randhoni Devi, Dr. R. K. Praneswori Devi, Dr. L. Ajit Kumar, Dr. Romita Devi, Dr. Sujit Das*,
Dr. Deepthambika and Dr. Abhipsa

ABSTRACT

Objective: To evaluate efficacies of oral nifedipine and intravenous labetalol in the management of severe pregnancy induced hypertension and analyse fetomaternal outcome. Methods: In this nonrandomised controlled study one hundred cases having severe pregnancy induced hypertension divided into two groups. Each group had 50 cases; nifedipine group and labetalol group. Patients in nifedipine group was given 10 mg initially, with repeated doses of 10 mg, every 15 minutes, for up to a maximum of 5 doses, or until the goal blood pressure less than or equal to 150/100 mm Hg was attained. Patients in intravenous labetalol group, was given 20 mg initially followed by escalating doses of 40 mg, 80mg, and then 80 mg, every 15 minutes, until the therapeutic goal blood pressure was achieved, or for a maximum of five doses. Corresponding placebos either 0.9% isotonic saline solution or inactive tablet was given simultaneously in each regimen. If therapeutic blood pressure was not achieved over 5 doses then cross over treatment was given. Results: The results of the study showed that the mean time required to achieve target blood pressure is 71.00±66.60 minutes in labetalol group and 25.20±14.03 minutes in the nifedipine group with the p value of < 0.01. The nifedipine group required in average 1.12±.32 doses to bring about the desired action and the labetalol group required 2.04±1.37 doses to bring about the same action which is statistically very highly significant (‘P’ value <0.01). Urine output at 60 minutes of commencing treatment is 55.20±16.72 ml in labetalol group compared to 99.10 ± 27.15 ml in nifedipine group with a ‘P’ value <.001. urine output at 60 minutes of commencing treatment is 55.20±16.72 ml in labetalol group compared to 99.10 ± 27.15 ml in nifedipine group with a ‘P’ value <.001. 10% failure rate is noted only in labetalol group requiring cross over treatment (P = 0.22). Fetomaternal outcome was more or less similar in both the group. Only one case of maternal mortality was seen in labetalol group as a result of eclampsia related complications. Conclusion: Both oral nifedipine and intravenous labetalol are effective in the management of severe pregnancy induced hypertension; however oral nifedipine controls hypertension more rapidly and with fewer doses and is associated with a significant increase in urinary output.

Keywords: Oral Nifedipine and Intravenous Labetalol.


[Full Text Article]

INDEXING

NEWS & UPDATION

  • New Issue Published

    Its Our pleasure to inform you that, EJPMR 1 November 2017 Issue has been Published, Kindly check it on http://www.ejpmr.com/home/current_issues

  • EJPMR NOVEMBER ISSUE PUBLISHED

    NOVEMBER 2017 Issue has been successfully launched on 1 November 2017

  • EJPMR New Impact Factor

    Its our Pleasure to Inform you that EJPMR Impact Factor has been increased from 3.628 to 4.161 due to high quality Publication at International Level

  • Index Copernicus Value

    EJPMR Received Index Copernicus Value 45.77, due to High Quality Publication in EJPMR at International Level

  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.

    .

  • Article Invited for Publication

    Article are invited for publication in EJPMR Coming Issue

Google Scholar Indian Science Publications InfoBase Index (In Process) SOCOLAR, China Research Bible, Fuchu, Tokyo. JAPAN International Society for Research activity (ISRA) Scientific Indexing Services (SIS) Polish Scholarly Bibliography Global Impact Factor (GIF) (Under Process) Universal Impact Factor International Scientific Indexing (ISI), UAE Index Copernicus CAS (A Division of American Chemical Society) USA (Under Process) Directory of Open Access Journal (DOAJ, Sweden, in process) UDLedge Science Citation Index CiteFactor Directory Of Research Journal Indexing (DRJI) Indian citation Index (ICI) Journal Index (JI, Under Process) Directory of abstract indexing for Journals (DAIJ) Open Access Journals (Under Process) Impact Factor Services For International Journals (IFSIJ) Cosmos Impact Factor Jour Informatics (Under Process) Eurasian Scientific Journal Index (ESJI) International Innovative Journal Impact Factor (IIJIF) Science Library Index, Dubai, United Arab Emirates Pubmed Database [NLM ID: 101669306] (Under Process)